The goal in demanding the introduction of the mechanism was that multiple companies would immediately trigger independent reviews with US Government support, draw attention to problems in decision-making, essentially overwhelm the system, and force further reform discussions. None of this happened, the US Government quickly lost confidence in the industry, and the Australian Government more successfully leveraged the agreement outcome.
Why the failure of a hard-won process reveals so much about an intractable problem
January 16, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Neurizon Therapeutics entering 'a promising new horizon” as ALS program advances
November 26, 2025 - - Australian Biotech -
Slade Pharmacy marks anniversary with record research contributions at conferences
November 26, 2025 - - Latest News -
US secures significant price reductions on 15 medicines in second round of medicare negotiations
November 26, 2025 - - Latest News -
The US and UK edging close to an agreement on pharmaceutical pricing
November 26, 2025 - - Latest News -
US Medicare sets reimbursement price for PromarkerD, paving way for major commercial rollout
November 26, 2025 - - Australian Biotech -
Recce reports strong preclinical efficacy for inhaled R327 in hospital-acquired pneumonia model
November 26, 2025 - - Australian Biotech -
Race Oncology secures human ethics approval for lung cancer trial of RC220
November 26, 2025 - - Australian Biotech
